GB2163160A - Process for the preparation of an aminolactone - Google Patents

Process for the preparation of an aminolactone Download PDF

Info

Publication number
GB2163160A
GB2163160A GB08520403A GB8520403A GB2163160A GB 2163160 A GB2163160 A GB 2163160A GB 08520403 A GB08520403 A GB 08520403A GB 8520403 A GB8520403 A GB 8520403A GB 2163160 A GB2163160 A GB 2163160A
Authority
GB
United Kingdom
Prior art keywords
compound
general formula
acid
yield
aqueous hydrochloric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08520403A
Other versions
GB8520403D0 (en
Inventor
Karoly Lempert
Gabor Doleschall
Jozsef Fetter
Gyula Hornyak
Jozsef Nyitrai
Gyula Simig
Karoly Zauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Works PLC
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Biogal Gyogyszergyar Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT, Biogal Gyogyszergyar Rt filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of GB8520403D0 publication Critical patent/GB8520403D0/en
Publication of GB2163160A publication Critical patent/GB2163160A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)

Abstract

An aminolactone of the formula (I), <IMAGE> is produced by a process, in which a) a compound of the general formula (III), wherein R represents a C1-6 alkyl group, <IMAGE> is subjected to reduction to yield a compound of the general formula (II> <IMAGE> wherein R has the same meaning as defined above, and the compound so obtained, in the presence of an alkanecarboxylic acid having a lower alkyl chain in the alkane moiety, is treated with a complex hydride and then with concentrated aqueous hydrochloric acid to yield the compound of the formula (I), or a2) a compound of the general formula (II), wherein R has the same meaning as defined above, in the presence of an alkanecarboxylic acid having a lower alkyl chain in the alkane moiety, is treated with a complex hydride and then with concentrated aqueous hydrochloric acid to yield the compound of the formula (I). The compound (I) is an intermediate for the known biotic thienamycin and related compounds.

Description

SPECIFICATION Novel process for the preparation of an aminolactone The -invention relates to a novel process for the preparation of an aminolactone of the formula (I).
The compound of the formula (I) is an intermediate in the total synthesis of the known antibiotic thienamycin and related compounds. Said total synthesis as well as the process for the preparation of the aminolactone are disclosed in the published European patent specification No. 32400. This process starts from di-ethyl (E)-2-acetyl-3-benzylamino-2-pentenedioate, which first is treated with cyanoborohydride and then with concentrated aqueous hydrochloric.acid, and after a reductive debenzylation step the aminolactone is obtained as an oil with a total yield of 20-25%.
Our aim was to find a better synthesis way for the preparation of the aminolactone. It has been found that via the reductive cleavage of an isoxazole derivative of the general formula (Ill)
wherein R represents a C16 alkyl group, a compound of the general formula (II) is obtained,
wherein R has the same meaning as given above, which is treated with a complex hydride and then with concentrated aqueous hydrochloric acid to yield the crystalline aminolactone with a total yield of 40%.
This synthesis route eliminates the introduction and the removal of the protective benzyl group, or in other-words, two essential steps of the previous process.
Starting substances of the general formula (III) as well as processes for the preparation thereof were disclosed in our previous Hungarian. patent applications Nos. 661/83 (=BE 899007) and 939/84, however, the method of their preparation is exemplified in the present application, too.
Thus; the- invention- relates to a process for the preparation of an aminolactone of the formula (I), in which al) a compound of the general formula (III), wherein R represents a C1 6 alkyl group, is subjected to reduction to::yield a compound of the general formula (II), wherein R has the same meaning as given above, and the compound so obtained, in the presence of an alkanecarboxylic acid having a lower alkyl chain in the alkane moiety, is treated with a complex hydride and then with concentrated aqueous hydro- chloric acid to yield the compound of the formula (I), or a2) a compound of the general formula (II), wherein R has the same meaning as given above, in the presence of an alkanecarboxylic acid having a lower alkyl chain in the alkane moiety, is treated with a complex hydride and then with concentrated aqueous hydrochloric acid to yield the compound of the formula (I).
According to process variant a1, the synthesis starts from an isoxazole derivative of the general formula (III), wherein R represents a C1 alkyl group, more particularly an ethyl or an n-butyl group. To convert the compound of the general formula (III) into the respective compound of the general formula (II) the starting substance is subjected to reduction, preferably to catalytic hydrogenation. The hydrogenation is accomplished in the presence of a platinum metal catalyst, preferably in the presence of paliadium-oncharcoal in a suitable organic solvent, i.e. in a lower alkanol or alkane-carboxylic acid, at atmospheric pressure.
The compound of the general formula (II) is then reacted with a complex hydride, more particularly with sodium borohydride or sodium cyanoborohydride in the presence ofa lower alkanecarboxylic acid, examples of which are glacial acetic acid or propionic acid, and then in the same medium is treated with concentrated aqueous hydrochloric acid. The treatment with said acid is accomplished at elevatedtem- perature, preferably at the boiling point of the reaction mixture.
According to a particularly preferred embodiment of the invention, the three reaction steps are carried out without recovering any of the intermediates, thus e.g. in glacial acetic acid in a one pot synthesis directly the aimed compound is obtained, which can be recovered after evaporation and crystallization.
The invention is elucidated in detail by the aid of the following non-limiting Examples.
Example I Dibutyl {EJ-Z-acetyl-3-amino-2-pentenedioate 20 g. (0.067 mole) of n-butyl 5-methyi-4-n--butoxyca rbonylisoxazole-3-yl-acetate is dissolved in 130 ml of methanol and is hydrogenated in the presence of 2 g. of palladium-on-charcoal at atmospheric pressure, at ambient temperature. When the hydrogenation has been completed, the reaction mixture is fil-.
tered off, and the filtrate is evaporated. The residue is triturated with pentane to give 17.8 g. (88%) of the crystalline title compound. Mp.: 45-46"C (pentane).
aH-NMR (CDCI3): 80.93 t (3H); 0.95 t (3H); 1.15-1.9 m (8H); 2.29 s (3H); 3.6 s (2H); 4.15 t (2H); 4.18 t (2H).
Two processes for the preparation of the starting substance are given below as method A and method B.
Method A A1) To a solution of 229 g. (10 mmoles) of ethyl trans-5-methyl-4-methoxycarbonyl-4,5-dihydroisoxazole- 3-yl-acetate in 7.5 ml. of tetrahydrofurane a solution of 5.68 g. (34 mmoles) of potassium iodide and 2.68 g. (10.5 mmoles) of iodine in 25 ml. of water is added and the reaction mixture is refluxed for 6 hours under stirring. The excess of iodine is decomposed with sodium hydrogen sulfite and then the reaction mixture is extracted five times with 10 ml. portions of dichloromethane. The organic layers are combined, washed twice with 10 ml. portions of saturated aqueous sodium chloride solution and finally the organic layer is dried over magnesium sulfate, filtered and the filtrate is concentrated.The residue is triturated with ether to yield 1.56 g. (79%) of crystalline 5- -methyl-4-methoxycarbonylisoxazole-3-yl-acetic acid. Mp.;135 C.
IR (KBr): 3500-2400, 1730 (sh), 1710, 1600 cm ,. aH-NMR (CDCl3): 8 2.63 s (3H); 3.76 s (3H); 3.88 s (2H); 10.10 s (1H).
A2)-To 1.99 g. (10 mmoles) of 5-methyl-4--methoxycarbonylisoxazole-3-yl-acetic acid prepared accord- ing to step A1, 10 ml. of water and 10 ml. of concentrated aqueous hydrochloric acid are added, and the emulsion so obtained is refluxed for two hours. The resulting solution is clarified in hot state, filtered off and the filtrate is concentrated to the half of its volume. Upon cooling the residue crystallizes. The crystalline product is filtered off and dried yielding 1.78 g. (96%) of 4-carboxy-5-methylisoxazole-3-yl-acetic acid. Mp.: 230 (Water).
IR (KBr): 3600-2400, 1720, 1690, 1610 cm-1. - 1H-NMR (D2O): 3 2.55 s (3H); 3.85 s (2H).
aH-NMR (DMSO-d6): 5 2.4 s (3H); 3.55 s (2H).
A3) 13 g. (70.2 mmoles) of 4-carboxy-5-methyl-isoxazole-3-yl-acetic acid prepared according to step A2) are refluxed in a mixture of 60 ml. of n-butanol, 150 ml. of benzene and 15 ml. concentrated sulphuric acid for 16 hours using a reflux condenser equipped with a water separator. Then the reaction mixture is poured onto ice. The phases are separated. The aqueous layer is extracted twice with 75 ml. portions of benzene. The organic phases are combined, washed twice with 100 ml. portions of water, then twice with 75 ml. portions of 5% aqueous solution of sodium hydrogen carbonate and then twice again with 75 ml.
portions of water. The organic layer is dried over calcium chloride and then the solvent is distilled off in vacuo to give 23 g. product as an oil, directly applicable without further purification. If desired, it can be purified by distillation in vacuo (Bp.: 130-131 C/0.1 Hgmm) to yield the pure n-butyl 5-methyl-4-n-butoxycarbonylisoxazole-3-yl-acetate.
Method B) B1) 350 g. (1.88 moles) of O-ethoxymethylene-acetoacetate are dissolved in 400 ml. of ethanol. To this solution 154 g. (2.2 moles) of hydroxylamine hydro-chlorid in 500 ml. water and 180 g. (2.2 moles) of sodium acetate are added, and the resulting solution is refluxed for 30 minutes. The reaction mixture is poured into 2 liters of water and the phases are separated. The aqueous layer is extracted three times with 250 ml. portions of dichloromethane, the extracts are combined with the organic layer and washed twice with 300 ml. portions of water. The phases are separated, and from the organic layer the dichloro methane is distilled off in vacuo to give 281 g. (96%) of ethyl 5-methyl-4-isoxazolecarboxylate; b.p.: 58-60 "C (0.3 Hgmm), which can be used in the further reaction steps without purification.
1H-NMR (CDCl3): 3 1.4 t (3H); 2.7 s (3H); 4.25 q (2H); 8.5 s (1H).
B2) 2.81 g. (1.81 moles) of the product obtained in step B,) are refluxed in a mixture of 200 ml. of glacial acetic acid, 200 ml. of water and 200 ml. of concentrated aqueous hydrochloric acid for 8 hours.
Then the reaction mixture is evaporated to dryness. To the residue 400 ml. of acetone are added and is then distilled off. The residue is dried to give 201 g. (87%) of 5-methyl-4-isoxazolecarboxylic acid; m.p.: 146-147 C (toluene).
B3) To 201 g. (1.58 moles) of the product obtained in step B2) 350 ml. of thionyl chloride are added stirring within 10 minutes, and then-the reaction mixture is refluxed on an oil bath of 120 "C temperature over one hour. The excess of the thionyl chloride is distilled off and the residue is purified by distillation in vacuo to yield 191 g. (83%) of 5-methyl-4-isoxazolecarboxylic acid chloride; bp.: 100-102 "C/18 Hgmm.
Analysis calculated for C5H4ClNO2 (145.55): C 41.25; H 2.77; N 9.68; C1 24.36%; found: C 41.17; H 2.92; N 9.57; Cl 24.22%.
B4) 66.5 g. (2.73 atoms) of magnesium chips are refluxed in a mixture of 20 ml. of ethanol and 1 ml. of carbon tetrachloride. To this boiling mixture 436 ml. (2.73 moles) of diethyl malonate are added in a mixture of 600 ml. benzene and 140 ml. of ethanol within an hour and thereafter the reaction mixture is refluxed for additional 3 hours. About a 500 ml. portion of the solvent is distilled off from the reaction mixture and to the residue first 400 ml. of dioxane and then in 200 ml of benzene 191 g. of the product obtained in step B3) are added under vigorous stirring at 35-400C. The reaction mixture is stirred for additional 10 minutes, then cooled and poured into a mixture of 400 ml of concentrated aqueous hydrochloric acid, 600 g. of ice and 1 liter of water.The phases are separated, the aqueous layer is extracted twice with 300 ml. portions of benzene. The organic layers are combined and washed first with a mixture of 80 ml. of concentrated aqueous hydrochloric acid and 400 ml. of water and then twice with 400 ml. portions of water. The organic layer is filtered, and its benzene content is distilled off. To the residue first 1 liter of dichloro-methane is added and distilled off, and then the excess of the diethyl malonate is removed over an oil bath of 135-140 "C temperature (bp.: 70--80 "C/0.4 Hgmm; about 230 ml.). Upon cooling from the residue crystalline ethyl 1-ethyoxycarbonyl-2-hydroxy--2-(5-methyl-4-isoxazolyl)acrylate is obtained with a yield of 330 g. (94%), bp.: 140-144 "C/0.4 Hgmm; mp.: 56 C (1:1 ether-hexane).
H-NMR (CDCI3); ;; 1.3 t (3H); 2.7 s (3H); 4.25 q (2H); 4.9 s (1H); 8.5 s (1H).
B5) 292 g. (1.08 moles) of the product obtained in step B4) is refluxed in 1 liter of ethanol with 100 g.
(1.45 moles of hydroxylamine hydrochloride. Then the reaction mixture is concentrated, the warm residue is dissolved in 1.2 liters of dichloromethane and filtered. The precipitate is washed twice with 200 ml.
portions of dichloromethane. The washings are combined with the filtrate, washed twice with 300 ml.
portions of water. The organic layer is concentrated in vacuo. To the residue 750 ml. of dichloromethane is added and then distilled off, the residue is triturated with 120 ml. of ethyl acetate and is left to stand at 0 C temperature. The crystals are filtered, washed twice with 25 ml. portions of cold ethyl acetate, then twice with 200 ml. portions of n-hexane and dried to yield 154 g. (62 %) of ethyl 3-(5-methyl-4-isoxazolyl)5-hydroxy--4-isoxazolecarboxylate; mp.: 153-154 C (ethyl acetate).1H-NMR (DMSO-d6): 3 1.1 t (3H); 2.4 s (3H); 4.0 q (2H); 8.6 s (1H); 11.0 s (1H).
B5) 154 g. (0.646 mole) of the product obtained in step B6) is refluxed in 650 ml. of acetic acid in the presence of 14 ml. of concentrated sulphuric acid for 15 minutes. After the evolution of carbon dioxide has terminated, 40 g. of sodium acetate is added to the solution which is then concentrated in vacuo. To the residue 300 ml. of water is added and is extracted twice with 500 ml. portions of dichloromethane.
The organic layers are combined, washed twice with 250 ml. portions of water and the organic layer is concentrated. First 500 ml. of dichloromethane and then 300 ml. of n-heptane is distilled off from the residue which finally is recrystallized from 130 ml. of 2-propanol. The crystals are filtered, washed twice with 15 ml. portions of ice--cold 2-propanol and then twice with 75 ml. portions of n-hexane and dried in the air to yield 93.4 g (87 %) of 3-(5-methyl-4-isoxazolyl)-4,5-dihydro.5-isoxazolone; mp. 94-95 "C.
rH-NMR (CDCl3): 3 2.7 s (3H); 3.8 s (2H); 8.4 s (1H).
B7) To a solution -of 57 g. (1.42 moles) of sodium hydroxide in 350 ml. of water, 93.4 g. (0.563 mole) of the compound obtained in step B6) are added in one portion, under stirring at 25"C. Stirring is continued for about 2 minutes while the temperature raises to about 70 "C. The reaction mixture is cooled on an ice-water bath and then 150 ml. of concentrated aqueous hydrochloric acid is added to the mixture which is then repeatedly cooled. The reaction mixture is extracted first with 300 ml. and then twice with 150 ml.
portions of dichloromethane. The phases are separated, the organic layer is washed twice with 80 ml.
portions of saturated aqueous sodium chloride solution and then is concentrated in vacuo. From the resi due first 250 ml. of dichloro-methane and then 150 ml. of n-hexane are distilled off. From the residue upon standing crystalline 4-cyano-5--methyl-3-isoxazoleacetic acid is obtained with a yield of 91.5 g.
(98%); m.p.: 90-91 "C (benzene).
H-NMR (CDCI3): 3 2.6 s (3H); 4.0 s (2H).
B8) In a mixture of 1-00 ml. of water and 100 ml. of concentrated aqueous hydrochloric acid 91.5 g. (0.55 mole) of the compound obtained in step B7) are refluxed for 3 hours. The reaction mixture is cooled, the precipitated product is washed twice with ice-cold water and dried in the air to give 95.7 g. (92%) of 4carboxy-5-methyl-3-isoxazoleacetic acid, a product with identical characteristics as given in step A2).
Example 2 (2RS, 3RS, 4SRj-4-amino-2-methyI-6-oxo-ttra-hydrop yrane3-carbaxylic acid hydrochloride 10 g. (0.033A mole) of dibutyl (E)-2-acetyl--3-amino-2-pentenedioate prepared according to Example 1 are dissolved in 60 ml. of glacial acetic acid. To this solution 3.8 g. (100 mmoles) of sodium borohydride are added under stirring and external cooling over about 2 hours. The reaction mixture is left to stand at room temperature overnight, thereupon is concentrated in vacuo. The residue is partitioned between 100 ml. of 10% aqueous sodium carbonate solution and 100 ml of ethyl acetate and then solid sodium carbonate is added until the bu Sling is ceased. The phases are separated, the aqueous layer is back-extracted twice with 20 ml. portions of ethyl acetate.The organic layers are combined, dried over magnesium sulfate, filtered and the filtrate is concentrated. To the residue 40 ml. of 20% aqueous hydrochloric acid solution are added, the mixture is refluxed over 5 hours, then concentrated. The residue is dissolved in 10 ml. of concentrated aqueous hydrochloric acid at 40-50 "C, then cooled to -10"C to give 39. (43%) of the title compound as a crystalline solid; mp.: 150-155 "C (dec.) 'H-NMR (CD3OD): 3- 1.36 d (3H, J = 6.5 Hz); 2.82 t (1H, J = 3.5 Hz); 2.85 d (2H, J = 6.5 Hz); 3.98 dt (1H. J = 6.5 and 3.5 Hzl; 4.30 dq (J = 6.5 and 3.5 Hz).
Example 3 (2RS, 3RS, 4SRJ-4-amino-2-methyl-6-oxo-tetra-hydropyrane-3-carboxylic acid hydrochloride 70 g. (0.235 mole) of n-butyl (5-methyl-4--n-butoxycarbonylisoxazole-3-yl)-acetate are dissolved in 350 ml. of glacial acetic acid, and are hydrogenated in the presence of 14 g. of palladium-on-charcoal catalyst at atmospheric pressure. The temperature of the reaction mixture araises to about 40 "C. After the reaction has been finished, the catalyst is filtered off, and to the filtrate 26.8 g. (0.705 mole) of sodium borohydride are added under external ice cooling within about 2 hours. The reaction mixture is stirred at ambient temperature for 3 hours, left to stand overnight and then concentrated in vacuo. The residue is partitioned between 300 ml. of ethyl acetate and 300 ml. saturated aqueous sodium hydrogen carbonate solution, then under vigorous stirring solid sodium hydrogen carbonate is added until the bubbling is ceased. The- phases are separated, the aqueous layer is extracted twice with 50 ml. portions of ethyl acetate. The organic layers are combined, dried over magnesium sulfate, filtered and the filtrate is concentrated.
The residue is taken up with 200 ml. of 20% aqueous hydrochloric acid solution, refluxed for 5 hours and then concentrated. The residue is dissolved in 70 ml. of concentrated aqueous hydrochloric acid under moderate heating and then crystallized in a deep freezer to give 19.8 g. (40%) of the title compound.
The physical constants are identical with those given in the previous example.

Claims (4)

1. A process for the preparation of an aminolactone of the formula (I),
which comprises a1) reducing a compound of the general formula (III),
wherein R represents a C,6 alkyl group, to yield a compound of the general formula (II),
wherein R has the same meaning as given above, treating the latter compound in the presence of an alkanecarboxylic acid having a lower alkyl chain in the alkane moiety, with a complex hydride and then with concentrated aqueous hydrochloric acid and recovering the amino-lactone, or a2) treating a compound of the general formula (it), wherein R has the same meaning as given above, in the presence of an alkanecarboxylic acid having a lower alkyl chain in the alkane moiety, with a complex hydride and then with concentrated aqueous hydrochloric acid, and recovering the aminolactone.
2. A process of claim 1, method a1) wherein the reduction is catalytic hydrogenation.
3. A process of claim 1, method a1 or a2, wherein the complex hydride is sodium borohydride or sodium cyanoborohydride.
4. A process of claim 1, substantially as hereinbefore described with reference to the Examples.
GB08520403A 1984-08-15 1985-08-14 Process for the preparation of an aminolactone Withdrawn GB2163160A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU309084A HU194203B (en) 1984-08-15 1984-08-15 Process for producing amino-lactone

Publications (2)

Publication Number Publication Date
GB8520403D0 GB8520403D0 (en) 1985-09-18
GB2163160A true GB2163160A (en) 1986-02-19

Family

ID=10962501

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08520403A Withdrawn GB2163160A (en) 1984-08-15 1985-08-14 Process for the preparation of an aminolactone

Country Status (10)

Country Link
JP (1) JPS61246176A (en)
BE (1) BE903069A (en)
CH (1) CH666686A5 (en)
DE (1) DE3529159A1 (en)
ES (1) ES8609297A1 (en)
FR (1) FR2569194B3 (en)
GB (1) GB2163160A (en)
HU (1) HU194203B (en)
PT (1) PT80959B (en)
SE (1) SE453193B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984738B2 (en) 2002-10-18 2006-01-10 Tohru Yokozawa Process for production of optically active amino alcohols
WO2007086076A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited An improved process for preparation of leflunomide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531638D0 (en) * 1985-12-23 1986-02-05 Ici Plc Chemical compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032400A1 (en) * 1980-01-14 1981-07-22 Merck & Co. Inc. (3SR, 4RS)-3-((RS)-1-hydroxyethyl)- and -((RS)-1-acyloxyethyl)-2-oxo-4-azetidineacetic acid compounds and a process for preparing the same
EP0062840A1 (en) * 1981-04-08 1982-10-20 Merck & Co. Inc. Process for the preparation of (2S)-tetrahydro-2alpha-methyl-6-oxo-4beta-amino-2H-pyran-3alpha-carboxylic acid esters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032400A1 (en) * 1980-01-14 1981-07-22 Merck & Co. Inc. (3SR, 4RS)-3-((RS)-1-hydroxyethyl)- and -((RS)-1-acyloxyethyl)-2-oxo-4-azetidineacetic acid compounds and a process for preparing the same
EP0062840A1 (en) * 1981-04-08 1982-10-20 Merck & Co. Inc. Process for the preparation of (2S)-tetrahydro-2alpha-methyl-6-oxo-4beta-amino-2H-pyran-3alpha-carboxylic acid esters

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984738B2 (en) 2002-10-18 2006-01-10 Tohru Yokozawa Process for production of optically active amino alcohols
WO2007086076A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited An improved process for preparation of leflunomide
WO2007086076A3 (en) * 2006-01-24 2009-04-30 Unichem Lab Ltd An improved process for preparation of leflunomide

Also Published As

Publication number Publication date
SE453193B (en) 1988-01-18
ES8609297A1 (en) 1986-09-01
HU194203B (en) 1988-01-28
SE8503811D0 (en) 1985-08-14
DE3529159A1 (en) 1986-02-27
BE903069A (en) 1986-02-14
HUT37777A (en) 1986-02-28
FR2569194B3 (en) 1987-06-26
FR2569194A1 (en) 1986-02-21
GB8520403D0 (en) 1985-09-18
JPS61246176A (en) 1986-11-01
CH666686A5 (en) 1988-08-15
PT80959B (en) 1987-02-06
ES546140A0 (en) 1986-09-01
SE8503811L (en) 1986-02-16
PT80959A (en) 1985-09-01

Similar Documents

Publication Publication Date Title
JPH07138228A (en) Intermediate compound and its preparation
US7342035B2 (en) Process for preparing zolmitriptan compounds
JPH04224575A (en) Synthesis of (s)-3-(thien-2-ylthio)- butylic acid analogue
GB2163160A (en) Process for the preparation of an aminolactone
JPH0432063B2 (en)
EP0172719B1 (en) Process for the production as asymmetric hydantoins
JP2000327603A (en) Production of propionic acid derivative
JPH06184069A (en) Production of alpha-hydroxy-beta-aminocarboxylic acid
JP2001521498A (en) Method for producing O- (3-amino-2-hydroxy-propyl) -hydroxymic acid halide
JP2001516738A (en) A novel stereoselective method for preparing gabapentin analogs
JPH0631249B2 (en) Method for producing thiophane derivative
JPH07215952A (en) Catechol derivative
JPS6355512B2 (en)
US7375245B2 (en) N-(4-oxo-butanoic acid) -L-amino acid-ester derivatives and methods of preparation thereof
WO1995022533A1 (en) Process for producing 3-isoxazolecarboxylic acid
JPH0129793B2 (en)
JPH069553A (en) Preparation of 1-(2s-methyl-3-mercaptopropionyl)- pyrrolidine-2s-carboxylic acid
JPH09169733A (en) Production of 4-trifluoromethylnicotinic acid
JP2005145833A (en) Method for producing syn-1,3-diol compound
WO1987006230A1 (en) Method for preparing penicillanic acid derivatives
EP0003847A1 (en) Biphenylylglycine derivatives and their salts with bases
JPH05345783A (en) Production of adenine derivative
JPS6056955A (en) Heterocyclic acetic acid ester
JPH054384B2 (en)
JPH11302216A (en) Production of dialkoxy-substituted indanone derivative

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)